Tag

cantargia

Göran Forsberg, CEO, Cantargia

Cantargia’s IND application for CAN04 approved by FDA

May 4, 2020

Cantargia has announced that its …

Cantargia

Cantargia acquires Cellerant IP on IL1RAP

March 12, 2020

Cantargia has announced the acquisition …

Cantargia

Cantargia completes a directed share issue of approximately 410 million SEK

February 20, 2020

Through the Directed Share Issue, …

cantargia

Cantargia selects CAN10 as development project in systemic sclerosis and myocarditis

December 12, 2019

Cantargia has announced that its …

Cantargia

An opposition has been filed against one of Cantargia’s patents

October 16, 2019

An opposition has been filed …

cantargia-goran

Cantargia submits request for pre-IND meeting

October 6, 2019

The company announced last month …

cantargia

Positive preclinical data from Cantargia

August 26, 2019

The company has announced new …

Cantargia CEO

Cantargia makes directed share issue of approximately SEK 106 million

March 22, 2019

The proceeds from the share …

cantargia

First patient treated in Cantargia’s CANFOUR trial

October 16, 2017

The first patient in the …

patent

US patent approval for Cantargia

October 9, 2017

Cantargia announces that the United …

Cantargia CEO

Business in focus: Cantargia

October 6, 2017

Swedish biotech company Cantargia recently …

cantargia-goran

New patent approval for Cantargia

September 1, 2017

Cantargia announces that the European …

cantargia-goran

Cantargia gains approval to initiate clinical trial

August 3, 2017

Cantargia’s clinical trial application to …

göran-cantargia

Cantargia enters collaboration agreement

June 16, 2017

Swedish Cantargia and Panorama Research …

göran-cantargia

Cantargia initiates clinical trial

May 15, 2017

Cantargia has submitted the first …

göran-cantargia

Cantargia receives Intention to Grant Notice in Europe

April 10, 2017

Cantargia announces that the company …

1
2